<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620330</url>
  </required_header>
  <id_info>
    <org_study_id>VS-6766-202</org_study_id>
    <nct_id>NCT04620330</nct_id>
  </id_info>
  <brief_title>A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer</brief_title>
  <acronym>RAMP-202</acronym>
  <official_title>A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) as a Single Agent and In Combination With Defactinib (FAK Inhibitor) in Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verastem, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verastem, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of VS-6766 monotherapy or VS-6766 in&#xD;
      combination with defactinib in subjects with recurrent Non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, non-randomized, open-label Phase 1b/2 study designed to evaluate&#xD;
      safety and tolerability and efficacy of VS-6766 versus VS-6766 in combination with defactinib&#xD;
      in subjects with KRAS-MT NSCLC following treatment with an appropriate platinum-based regimen&#xD;
      and an approved immune checkpoint inhibitor (CPI).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 31, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib,</measure>
    <time_frame>From start of treatment to confirmation of response; 24 weeks</time_frame>
    <description>Confirmed overall response rate per RECIST 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: To determine the efficacy of the optimal regimen identified from Part A</measure>
    <time_frame>From start of treatment to confirmation of response; 24 weeks</time_frame>
    <description>Confirmed overall response rate per RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate as assessed by Investigator</measure>
    <time_frame>From start of treatment to confirmation of response; 24 weeks</time_frame>
    <description>Proportioned subjects achieving a CR or PR as assess by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Time from the first documentation of response to first documentation of progressive disease or death due to any cause, greater than or equal to 6 months</time_frame>
    <description>Time of first response to PD as assessed by the IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Greater than or equal to 8 weeks</time_frame>
    <description>CR and PR stable disease as assessed by the IRC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From the time of first dose of study intervention to PD or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>From time of first dose of study intervention to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <condition>KRAS Activating Mutation</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the optimal regimen, either VS-6766 monotherapy or VS-6766 in combination with defactinib, for subsequent evaluation for efficacy in the expansion phase (Part B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To determine the efficacy of the optimal regimen identified from Part A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS-6766</intervention_name>
    <description>Monotherapy</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VS-6766 and Defactinib</intervention_name>
    <description>Combination therapy</description>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
    <other_name>VS-6766 and VS-6063</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects ≥ 18 years of age&#xD;
&#xD;
          -  Histologic or cytologic evidence of NSCLC&#xD;
&#xD;
          -  Known KRAS mutation&#xD;
&#xD;
          -  The subject must have received appropriate prior therapy&#xD;
&#xD;
          -  Measurable disease according to RECIST 1.1&#xD;
&#xD;
          -  An Eastern Cooperative Group (ECOG) performance status ≤ 1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
          -  Adequate recovery from toxicities related to prior treatments&#xD;
&#xD;
          -  Agreement to use highly effective method of contraceptive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic anti-cancer therapy within 4 weeks of the first dose of study therapy&#xD;
&#xD;
          -  History of prior malignancy, with the exception of curatively treated malignancies&#xD;
&#xD;
          -  Major surgery within 4 weeks (excluding placement of vascular access)&#xD;
&#xD;
          -  History of treatment with a direct and specific inhibitor of MEK or KRAS&#xD;
&#xD;
          -  Exposure to strong CYP2C9 and CYP3A4 inhibitors or inducers within 7 days prior to the&#xD;
             first dose and during the course of therapy&#xD;
&#xD;
          -  Symptomatic brain metastases requiring steroids or other local interventions.&#xD;
&#xD;
          -  Known SARS-Cov2 infection ≤28 days prior to first dose of study therapy&#xD;
&#xD;
          -  Active skin disorder that has required systemic therapy within the past 1 year&#xD;
&#xD;
          -  History of rhabdomyolysis&#xD;
&#xD;
          -  Concurrent ocular disorders&#xD;
&#xD;
          -  Concurrent heart disease or severe obstructive pulmonary disease&#xD;
&#xD;
          -  Subjects with the inability to swallow oral medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Camidge, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagop Youssoufian, MD</last_name>
    <role>Study Director</role>
    <affiliation>Verastem, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gloria Patrick</last_name>
    <phone>781-469-1594</phone>
    <email>gpatrick@verastem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Matt Mockler</last_name>
    <phone>781-292-4201</phone>
    <email>mmockler@verastem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Salgia</last_name>
      <phone>626-218-8900</phone>
      <email>rsalgia@coh.org</email>
    </contact>
    <investigator>
      <last_name>Ravi Salgia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cole Sprague</last_name>
      <phone>720-848-8030</phone>
      <email>COLE.SPRAGUE@CUANSCHUTZ.EDU</email>
    </contact>
    <investigator>
      <last_name>Ross Camidge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hedge</last_name>
      <phone>303-385-2067</phone>
      <email>Jennifer.Hege@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Robert M Jotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Reuss</last_name>
      <email>Joshua.E.Reuss@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Joshua Reuss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Faithlore Gardner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Sunil Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin T Davis</last_name>
      <phone>404-778-1900</phone>
      <email>erin.t.davis@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Carlisle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dakota Horstman</last_name>
      <phone>312-695-1301</phone>
      <email>cancertrials@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Jyoti Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center-Duchossois Center for Advanced Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Intake</last_name>
      <phone>855-702-8222</phone>
      <email>cancerclinicaltrials@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Ardaman Shergill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Specialists</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbeth Lynn</last_name>
      <email>Lisbeth.lynn@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>David Hakimian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Clinic, LLP</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Michael Castine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology P.A</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Almand</last_name>
      <email>MOHRSCH@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Yousuf Gaffar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Farber Cancer Institute</last_name>
      <phone>877-338-7425</phone>
    </contact>
    <investigator>
      <last_name>Janne Pasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Cancer Institute/Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thoracic Oncology Clinical Research</last_name>
      <email>TOCResearch@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Shirish Gadgeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saiama Waqar, MD</last_name>
      <phone>314-747-8475</phone>
      <email>saiamawaqar@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Saiama Waqar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chelsea McCabe</last_name>
      <email>Chelsea.McCabe@hmhn.org</email>
    </contact>
    <investigator>
      <last_name>Martin Gutierrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Bigler</last_name>
      <email>Margaret.Bigler@USONCOLOGY.COM</email>
    </contact>
    <investigator>
      <last_name>Robert Lufkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Edelman</last_name>
      <email>martin.edelman@fccc.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Treat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. of Pittsburgh Med Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Ruth</last_name>
      <email>ruthj2@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Burns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Assoc.</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>037404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Davey Daniel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cannon Research Site</last_name>
      <phone>844-482-4812</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>David Spigel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Ft Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nori Sullivan</last_name>
      <email>Nori.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Asad Dean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Springer</last_name>
      <email>Sonya.Springer@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Heidi Jordan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Keaton</last_name>
      <phone>713-792-5122</phone>
      <email>dkeaton@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>George Blumenschien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcy Sullivan</last_name>
      <email>marcy.sullivan@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Novello</last_name>
      <phone>39 0119026978</phone>
      <email>silvia.novello@unito.it</email>
    </contact>
    <investigator>
      <last_name>Silvia Novello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemi Reguart Aransay</last_name>
      <phone>+34 93 227 54 02</phone>
      <email>nreguart@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Noemi Reguart Aransay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universiario a Coruna Teresa</name>
      <address>
        <city>Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Garcia Campelo</last_name>
      <phone>34 98 11 78000</phone>
    </contact>
    <investigator>
      <last_name>Maria Garcia Campelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Vicente Baz</last_name>
      <phone>34 955 00 80 00</phone>
    </contact>
    <investigator>
      <last_name>David Vicente Baz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>KRAS-G12V</keyword>
  <keyword>G12V</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

